Less frequent intravenous dosing of nemvaleukin alfa in patients with advanced solid tumors: the phase 1/2 ARTISTRY-3 trial
Less frequent IV doses of nemvaleukin demonstrated pharmacodynamic proof of mechanism and were tolerable with some disease stabilization.
Authors
- Nehal J. Lakhani (ORCID: https://orcid.org/0009-0005-6327-0176)
- Sarina A. Piha‐Paul (ORCID: https://orcid.org/0000-0001-9455-1660)
- Xiwei Chen (ORCID: https://orcid.org/0000-0003-1868-8387)
- Alexander I. Spira (ORCID: https://orcid.org/0000-0003-1303-0447)
- Justin Call (ORCID: https://orcid.org/0000-0001-8227-7406)
- Maria J. de Miguel (ORCID: https://orcid.org/0000-0002-9366-8602)
- Jorge Bartolomé (ORCID: https://orcid.org/0000-0002-2715-6529)
- Sarah Donatelli
Institutions
- Van Andel Institute (US)
- The University of Texas MD Anderson Cancer Center (US)
- Hospital Clínico San Carlos (ES)
- Massachusetts Medical Society (US)
- Utah Valley Regional Medical Center (US)
- Michigan United (US)
- South Texas Accelerated Research Therapeutics (US)
- Fairfax Neonatal Associates (US)
- Hospital Universitario HM Sanchinarro (ES)
- TE Laboratories (Ireland) (IE)
- Start Treatment & Recovery Centers (US)
- Star Center (US)
Publication Details
- Journal
- The Oncologist
- Published
- 2025-09-23
- DOI
- https://doi.org/10.1093/oncolo/oyaf301
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- American Society of Clinical Oncology